secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2023-05-12T23:59:59+00:00
Accession:  0001558370-23-009512
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeuroBo appoints Mark A. Glickman to board of directors
-------------------------------------------------------

- Appointed effective May 11, 2023 as Class III director, term expiring at 2025 annual meeting.
- Glickman brings over 30 years pharma experience; most recently co-CEO of TherapeuticsMD (TXMD).
- Will receive standard non-employee director compensation: initial 40,000-share option grant and $40,000 annual cash retainer (pro-rated for 2023).
- Company plans Q3 2023 Phase 2a trial for DA-1241 (NASH) and IND for DA-1726 (GLP1R/GCGR) with Phase 1a in H1 2024.
- No family relationships or material arrangements with any other director or officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023009512/0001558370-23-009512-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837023009512/nrbo-20230511x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-009512

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer